ARVO 2018: Dr. Shannon Boye Reports on her Emerging Gene Therapy for LCA (GUCY2D)
Shannon Boye, PhD, University of Florida, talks about the advancement of her of gene therapy for Leber congenital amaurosis toward a clinical trial.
All Posts by
Shannon Boye, PhD, University of Florida, talks about the advancement of her of gene therapy for Leber congenital amaurosis toward a clinical trial.
An experimental treatment sacrifices rod cell function to save cone cells in mice, preventing retinal degeneration, researchers report. …
Shannon E. Boye, Ph.D., an assistant professor in the University of Florida College of Medicine’s department of ophthalmology, discusses her research involving developing gene therapies for devastating forms of blindness.
Dr. Boye received the Foundation’s Board of Director’s Award, which was presented at VISIONS 2015, FFB’s annual conference, for achievements in retinal research.
In medicine, doctors often talk about treatments, but rarely about cures. Now, gene therapy is offering the potential to actually cure certain diseases and an experimental breakthrough could one day help blind patients see.
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness. Leber congenital amaurosis type 1 (LCA-1)…
Much work is being done with Adeno-associated virus (AAV) vectors for application in retinal gene therapy, with modifications being made to the capsid and genome of the vector to generate novel variants with unique transduction profiles, according to Shannon Boye, PhD…
Dr. Boye and her research team received a $900,000 grant for a gene therapy project targeting Leber congenital amaurosis.